The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
Error code: JobManagerCrashedError
Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
id string | title string | content string | contents string |
|---|---|---|---|
NCT00000108_0 | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women | Protocol section details: Identification module details: Nct id is NCT00000108. Org study id info details: Id is NCRR-M01RR00042-1647. Secondary id infos includes Id is M01RR000042. Type is NIH. Link is https://reporter.nih.gov/quickSearch/M01RR000042. Organization details: Full name is National Center for Research Res... | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women. Protocol section details: Identification module details: Nct id is NCT00000108. Org study id info details: Id is NCRR-M01RR00042-1647. Secondary id infos includes Id is M01RR000042. Type is NIH. Link is https://reporter.nih.gov/quickSearch/M... |
NCT00000108_1 | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women | post date struct details: Date is 2005-06-24. Type is ESTIMATED. Sponsor collaborators module details: Lead sponsor details: Name is National Center for Research Resources (NCRR). Class is NIH. Description module details: Brief summary is The purpose of this research is to find out whether training at different exercis... | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women. post date struct details: Date is 2005-06-24. Type is ESTIMATED. Sponsor collaborators module details: Lead sponsor details: Name is National Center for Research Resources (NCRR). Class is NIH. Description module details: Brief summary is Th... |
NCT00000108_2 | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women | all of these risk factors and any changes in your body fat level before you start training and after 15 and 30 weeks of training in the form of walking. At the present time the effects of exercise intensity on these factors are not well understood. This study will add to the basic understanding of these issues and allo... | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women. all of these risk factors and any changes in your body fat level before you start training and after 15 and 30 weeks of training in the form of walking. At the present time the effects of exercise intensity on these factors are not well unde... |
NCT00000108_3 | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women | includes Type is BEHAVIORAL. Name is Exercise. Eligibility module details: Eligibility criteria is Inclusion Criteria: * Postmenopausal and preferably on hormone replacement therapy * In good general health * Have a body mass index (BMI, weight in kg/height in m2) of between 25 and 40 * Exercise less than 20 min/day tw... | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women. includes Type is BEHAVIORAL. Name is Exercise. Eligibility module details: Eligibility criteria is Inclusion Criteria: * Postmenopausal and preferably on hormone replacement therapy * In good general health * Have a body mass index (BMI, wei... |
NCT00000108_4 | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women | Condition browse module details: Meshes includes Id is D002318. Term is Cardiovascular Diseases, Id is D003327. Term is Coronary Disease. Ancestors includes Id is D017202. Term is Myocardial Ischemia, Id is D006331. Term is Heart Diseases, Id is D014652. Term is Vascular Diseases. Browse leaves includes Id is M6546. Na... | Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women. Condition browse module details: Meshes includes Id is D002318. Term is Cardiovascular Diseases, Id is D003327. Term is Coronary Disease. Ancestors includes Id is D017202. Term is Myocardial Ischemia, Id is D006331. Term is Heart Diseases, I... |
NCT00000110_0 | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA | Protocol section details: Identification module details: Nct id is NCT00000110. Org study id info details: Id is NCRR-M01RR00032-0855. Secondary id infos includes Id is M01RR000032. Type is NIH. Link is https://reporter.nih.gov/quickSearch/M01RR000032. Organization details: Full name is National Center for Research Res... | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA. Protocol section details: Identification module details: Nct id is NCT00000110. Org study id info details: Id is NCRR-M01RR00032-0855. Secondary id infos includes Id is M01RR000032. Type is NIH. Link is https://reporter.nih.gov/quick... |
NCT00000110_1 | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA | post date struct details: Date is 2005-06-24. Type is ESTIMATED. Sponsor collaborators module details: Lead sponsor details: Name is National Center for Research Resources (NCRR). Class is NIH. Description module details: Brief summary is The purpose of this pilot investigation is to use 1 H Magnetic Resonance Spectros... | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA. post date struct details: Date is 2005-06-24. Type is ESTIMATED. Sponsor collaborators module details: Lead sponsor details: Name is National Center for Research Resources (NCRR). Class is NIH. Description module details: Brief summa... |
NCT00000110_2 | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA | diet in 10 endurance trained athletes who will consume both diets in a randomly assigned cross-over fashion. We hypothesize that IML will be depleted with prolonged endurance exercise, and that replenishment of IML will be impaired by an extremely low-fat diet compared to a moderate-fat diet. Results of this pilot stud... | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA. diet in 10 endurance trained athletes who will consume both diets in a randomly assigned cross-over fashion. We hypothesize that IML will be depleted with prolonged endurance exercise, and that replenishment of IML will be impaired b... |
NCT00000110_3 | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA | includes exercise, exertion, physical fitness, lipids, nutrition. Design module details: Study type is INTERVENTIONAL. Phases includes NA. Design info details: Primary purpose is TREATMENT. Masking info details: Masking is SINGLE. Arms interventions module details: Interventions includes Type is PROCEDURE. Name is magn... | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA. includes exercise, exertion, physical fitness, lipids, nutrition. Design module details: Study type is INTERVENTIONAL. Phases includes NA. Design info details: Primary purpose is TREATMENT. Masking info details: Masking is SINGLE. Ar... |
NCT00000110_4 | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA | at Birmingham Nutrition Sciences Department. City is Birmingham. State is Alabama. Zip is 35294. Country is United States. Geo point details: Lat is 33.52066. Lon is -86.80249. Derived section details: Misc info module details: Version holder is 2025-03-28. Condition browse module details: Browse leaves includes Id is ... | Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA. at Birmingham Nutrition Sciences Department. City is Birmingham. State is Alabama. Zip is 35294. Country is United States. Geo point details: Lat is 33.52066. Lon is -86.80249. Derived section details: Misc info module details: Versi... |
NCT00000113_0 | Correction of Myopia Evaluation Trial (COMET) | Protocol section details: Identification module details: Nct id is NCT00000113. Org study id info details: Id is NEI-9. Secondary id infos includes Id is U10EY011756. Type is NIH. Link is https://reporter.nih.gov/quickSearch/U10EY011756. Organization details: Full name is Stony Brook University. Class is OTHER. Brief t... | Correction of Myopia Evaluation Trial (COMET). Protocol section details: Identification module details: Nct id is NCT00000113. Org study id info details: Id is NEI-9. Secondary id infos includes Id is U10EY011756. Type is NIH. Link is https://reporter.nih.gov/quickSearch/U10EY011756. Organization details: Full name is ... |
NCT00000113_1 | Correction of Myopia Evaluation Trial (COMET) | 1999-09-23. Study first submit qc date is 1999-09-23. Study first post date struct details: Date is 1999-09-24. Type is ESTIMATED. Last update submit date is 2016-04-14. Last update post date struct details: Date is 2016-04-15. Type is ESTIMATED. Sponsor collaborators module details: Lead sponsor details: Name is Stony... | Correction of Myopia Evaluation Trial (COMET). 1999-09-23. Study first submit qc date is 1999-09-23. Study first post date struct details: Date is 1999-09-24. Type is ESTIMATED. Last update submit date is 2016-04-14. Last update post date struct details: Date is 2016-04-15. Type is ESTIMATED. Sponsor collaborators modu... |
NCT00000113_2 | Correction of Myopia Evaluation Trial (COMET) | by A-scan ultrasonography. To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses). Detailed description is Myopia (nearsightedness) is an important public health problem, which entails substantial societal and personal costs. It is highly ... | Correction of Myopia Evaluation Trial (COMET). by A-scan ultrasonography. To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses). Detailed description is Myopia (nearsightedness) is an important public health problem, which entails substan... |
NCT00000113_3 | Correction of Myopia Evaluation Trial (COMET) | the Correction of Myopia Evaluation Trial (COMET), arises from the convergence of research involving (1) the link between accommodation and myopia in children and (2) animal models of myopia showing the important role of the visual environment in eye growth. A contribution of this research is that blur is a critical co... | Correction of Myopia Evaluation Trial (COMET). the Correction of Myopia Evaluation Trial (COMET), arises from the convergence of research involving (1) the link between accommodation and myopia in children and (2) animal models of myopia showing the important role of the visual environment in eye growth. A contribution... |
NCT00000113_4 | Correction of Myopia Evaluation Trial (COMET) | of PALs on myopia progression during the followup period. The COMET is a multicenter, randomized, double-masked clinical trial to evaluate whether PALs slow the progression of juvenile-onset myopia as compared with single vision lenses. The study is a collaborative effort that involves a Study Chair at the New England ... | Correction of Myopia Evaluation Trial (COMET). of PALs on myopia progression during the followup period. The COMET is a multicenter, randomized, double-masked clinical trial to evaluate whether PALs slow the progression of juvenile-onset myopia as compared with single vision lenses. The study is a collaborative effort ... |
NCT00000113_5 | Correction of Myopia Evaluation Trial (COMET) | children were randomly assigned to receive progressive addition or single vision lenses. Participating children are being examined at 6-month intervals following baseline, for at least 3 years, to measure changes in refractive error and to update prescriptions, according to a specified protocol. A dilated examination t... | Correction of Myopia Evaluation Trial (COMET). children were randomly assigned to receive progressive addition or single vision lenses. Participating children are being examined at 6-month intervals following baseline, for at least 3 years, to measure changes in refractive error and to update prescriptions, according t... |
NCT00000113_6 | Correction of Myopia Evaluation Trial (COMET) | Keywords includes myopia, nearsightedness. Design module details: Study type is INTERVENTIONAL. Phases includes PHASE3. Design info details: Allocation is RANDOMIZED. Intervention model is PARALLEL. Primary purpose is TREATMENT. Masking info details: Masking is TRIPLE. Who masked includes PARTICIPANT, INVESTIGATOR, OUT... | Correction of Myopia Evaluation Trial (COMET). Keywords includes myopia, nearsightedness. Design module details: Study type is INTERVENTIONAL. Phases includes PHASE3. Design info details: Allocation is RANDOMIZED. Intervention model is PARALLEL. Primary purpose is TREATMENT. Masking info details: Masking is TRIPLE. Who... |
NCT00000113_7 | Correction of Myopia Evaluation Trial (COMET) | +2.00 addition. Arm group labels includes Progressive Addition Lenses (PALs), Type is OTHER. Name is single vision lenses. Arm group labels includes Single Vision Lenses. Outcomes module details: Primary outcomes includes Measure is Progression of myopia, determined by cycloplegic autorefraction. Secondary outcomes inc... | Correction of Myopia Evaluation Trial (COMET). +2.00 addition. Arm group labels includes Progressive Addition Lenses (PALs), Type is OTHER. Name is single vision lenses. Arm group labels includes Single Vision Lenses. Outcomes module details: Primary outcomes includes Measure is Progression of myopia, determined by cyc... |
NCT00000113_8 | Correction of Myopia Evaluation Trial (COMET) | inclusion. Exclusion criteria include visual acuity greater than 20/25, strabismus, use of contact lenses, birth weight less than 1,250 grams, use of bifocal or progressive addition lenses, or any conditions precluding adherence to the protocol. Healthy volunteers is False. Sex is ALL. Minimum age is 6 Years. Maximum a... | Correction of Myopia Evaluation Trial (COMET). inclusion. Exclusion criteria include visual acuity greater than 20/25, strabismus, use of contact lenses, birth weight less than 1,250 grams, use of bifocal or progressive addition lenses, or any conditions precluding adherence to the protocol. Healthy volunteers is False... |
NCT00000113_9 | Correction of Myopia Evaluation Trial (COMET) | is 33.52066. Lon is -86.80249, Facility is New England College of Optometry. City is Boston. State is Massachusetts. Zip is 02115. Country is United States. Geo point details: Lat is 42.35843. Lon is -71.05977, Facility is Pennsylvania College of Optometry. City is Philadelphia. State is Pennsylvania. Zip is 19141-3399... | Correction of Myopia Evaluation Trial (COMET). is 33.52066. Lon is -86.80249, Facility is New England College of Optometry. City is Boston. State is Massachusetts. Zip is 02115. Country is United States. Geo point details: Lat is 42.35843. Lon is -71.05977, Facility is Pennsylvania College of Optometry. City is Philade... |
NCT00000113_10 | Correction of Myopia Evaluation Trial (COMET) | Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500. doi: 10.1167/iovs.02-0816, Pmid is 15223788. Type is RESULT. Citation is Gwiazda JE, Hyman L, Norton TT, Hussein ME, Marsh-Toot... | Correction of Myopia Evaluation Trial (COMET). Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500. doi: 10.1167/iovs.02-0816, Pmid is 15223788. Type is RESULT. Citation is Gwiazda... |
NCT00000113_11 | Correction of Myopia Evaluation Trial (COMET) | of myopia evaluation trial. Arch Ophthalmol. 2005 Jul;123(7):977-87. doi: 10.1001/archopht.123.7.977, Pmid is 24576881. Type is DERIVED. Citation is Deng L, Gwiazda J, Manny RE, Scheiman M, Weissberg E, Fern KD, Weise K; COMET Study Group. Limited change in anisometropia and aniso-axial length over 13 years in myopic c... | Correction of Myopia Evaluation Trial (COMET). of myopia evaluation trial. Arch Ophthalmol. 2005 Jul;123(7):977-87. doi: 10.1001/archopht.123.7.977, Pmid is 24576881. Type is DERIVED. Citation is Deng L, Gwiazda J, Manny RE, Scheiman M, Weissberg E, Fern KD, Weise K; COMET Study Group. Limited change in anisometropia a... |
NCT00000113_12 | Correction of Myopia Evaluation Trial (COMET) | info module details: Version holder is 2025-03-28. Condition browse module details: Meshes includes Id is D009216. Term is Myopia. Ancestors includes Id is D012030. Term is Refractive Errors, Id is D005128. Term is Eye Diseases. Browse leaves includes Id is M12168. Name is Myopia. As found is Myopia. Relevance is HIGH,... | Correction of Myopia Evaluation Trial (COMET). info module details: Version holder is 2025-03-28. Condition browse module details: Meshes includes Id is D009216. Term is Myopia. Ancestors includes Id is D012030. Term is Refractive Errors, Id is D005128. Term is Eye Diseases. Browse leaves includes Id is M12168. Name is... |
NCT00000114_0 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | Protocol section details: Identification module details: Nct id is NCT00000114. Org study id info details: Id is NEI-10. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. Status module detai... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. Protocol section details: Identification module details: Nct id is NCT00000114. Org study id info details: Id is NEI-10. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Randomized Trial of... |
NCT00000114_1 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | Type is ESTIMATED. Sponsor collaborators module details: Lead sponsor details: Name is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To determine whether supplements of vitamin A or vitamin E alone or in combination affect the course of retinitis pigmentosa. Detailed descripti... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. Type is ESTIMATED. Sponsor collaborators module details: Lead sponsor details: Name is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To determine whether supplements of vitamin A or vitamin E... |
NCT00000114_2 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | from most patients with remaining vision and thereby monitor objectively the course of their disease. While the natural course of retinal degeneration in the common forms of RP was being studied, it was noted that a subgroup of patients aged 18 through 49 who were treating themselves with both vitamin A and vitamin E a... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. from most patients with remaining vision and thereby monitor objectively the course of their disease. While the natural course of retinal degeneration in the common forms of RP was being studied, it was noted that a subgroup of patien... |
NCT00000114_3 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | and duration of 4 to 6 years. Patients were assigned to one of four treatment groups: 15,000 IU/day vitamin A 15,000 IU/day vitamin A + 400 IU/day vitamin E trace amounts of both vitamins A and E 400 IU/day of vitamin E The main outcome measure was the 30-Hz cone ERG amplitude. In addition, visual field and visual acui... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. and duration of 4 to 6 years. Patients were assigned to one of four treatment groups: 15,000 IU/day vitamin A 15,000 IU/day vitamin A + 400 IU/day vitamin E trace amounts of both vitamins A and E 400 IU/day of vitamin E The main outco... |
NCT00000114_4 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | is DRUG. Name is Vitamin A. Eligibility module details: Eligibility criteria is Men and nonpregnant women between ages 18 and 49 years with common forms of RP were included. All eligible patients had retinal arteriolar attenuation, elevated dark adaptation thresholds, and reduced ERGs. Patients had best corrected Snell... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. is DRUG. Name is Vitamin A. Eligibility module details: Eligibility criteria is Men and nonpregnant women between ages 18 and 49 years with common forms of RP were included. All eligible patients had retinal arteriolar attenuation, el... |
NCT00000114_5 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | patients had a total estimated pre-trial intake of vitamins A and E from diet plus pills not greater than 11,500 IU/day and 40 IU/day, respectively. Sex is ALL. Minimum age is 18 Years. Maximum age is 49 Years. Std ages includes ADULT. References module details: References includes Pmid is 8512476. Type is BACKGROUND. ... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. patients had a total estimated pre-trial intake of vitamins A and E from diet plus pills not greater than 11,500 IU/day and 40 IU/day, respectively. Sex is ALL. Minimum age is 18 Years. Maximum age is 49 Years. Std ages includes ADULT... |
NCT00000114_6 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | Ophthalmol Vis Sci. 1996 Jul;37(8):1693-8. Derived section details: Misc info module details: Version holder is 2025-03-28. Condition browse module details: Meshes includes Id is D012173. Term is Retinitis, Id is D012174. Term is Retinitis Pigmentosa. Ancestors includes Id is D012164. Term is Retinal Diseases, Id is D0... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. Ophthalmol Vis Sci. 1996 Jul;37(8):1693-8. Derived section details: Misc info module details: Version holder is 2025-03-28. Condition browse module details: Meshes includes Id is D012173. Term is Retinitis, Id is D012174. Term is Reti... |
NCT00000114_7 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | Name is Eye Diseases. Relevance is LOW, Id is M18339. Name is Eye Diseases, Hereditary. Relevance is LOW, Id is M29107. Name is Retinal Dystrophies. Relevance is LOW, Id is M14997. Name is Retinal Degeneration. Relevance is LOW, Id is M23686. Name is Genetic Diseases, Inborn. Relevance is LOW, Id is T4945. Name is Reti... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. Name is Eye Diseases. Relevance is LOW, Id is M18339. Name is Eye Diseases, Hereditary. Relevance is LOW, Id is M29107. Name is Retinal Dystrophies. Relevance is LOW, Id is M14997. Name is Retinal Degeneration. Relevance is LOW, Id is... |
NCT00000114_8 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | Id is D045505. Term is Physiological Effects of Drugs, Id is D000975. Term is Antioxidants, Id is D045504. Term is Molecular Mechanisms of Pharmacological Action, Id is D020011. Term is Protective Agents. Browse leaves includes Id is M17558. Name is Vitamins. As found is Every. Relevance is HIGH, Id is M17553. Name is ... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. Id is D045505. Term is Physiological Effects of Drugs, Id is D000975. Term is Antioxidants, Id is D045504. Term is Molecular Mechanisms of Pharmacological Action, Id is D020011. Term is Protective Agents. Browse leaves includes Id is ... |
NCT00000114_9 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | is Antioxidants. Relevance is LOW, Id is M21869. Name is Protective Agents. Relevance is LOW, Id is T480. Name is Vitamin E. As found is Days per. Relevance is HIGH, Id is T466. Name is Tocopherol. Relevance is LOW, Id is T467. Name is Tocotrienol. Relevance is LOW, Id is T462. Name is Retinol. Relevance is LOW, Id is ... | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. is Antioxidants. Relevance is LOW, Id is M21869. Name is Protective Agents. Relevance is LOW, Id is T480. Name is Vitamin E. As found is Days per. Relevance is HIGH, Id is T466. Name is Tocopherol. Relevance is LOW, Id is T467. Name i... |
NCT00000116_0 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | Protocol section details: Identification module details: Nct id is NCT00000116. Org study id info details: Id is NEI-12. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. Official title is Clinical... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. Protocol section details: Identification module details: Nct id is NCT00000116. Org study id info details: Id is NEI-12. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Randomized Trial of DHA fo... |
NCT00000116_1 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | 1999-09-23. Study first submit qc date is 1999-09-23. Study first post date struct details: Date is 1999-09-24. Type is ESTIMATED. Last update submit date is 2023-02-22. Last update post date struct details: Date is 2023-03-08. Type is ACTUAL. Sponsor collaborators module details: Responsible party details: Type is SPO... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. 1999-09-23. Study first submit qc date is 1999-09-23. Study first post date struct details: Date is 1999-09-24. Type is ESTIMATED. Last update submit date is 2023-02-22. Last update post date struct details: Date is 2023-03-08. Type is ACTUA... |
NCT00000116_2 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | Detailed description is Retinitis pigmentosa (RP) is a group of inherited retinal degenerations with a worldwide prevalence of approximately 1 in 4,000. Patients typically report night blindness and difficulty with midperipheral visual field in adolescence. As the condition progresses, they lose far peripheral visual f... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. Detailed description is Retinitis pigmentosa (RP) is a group of inherited retinal degenerations with a worldwide prevalence of approximately 1 in 4,000. Patients typically report night blindness and difficulty with midperipheral visual field... |
NCT00000116_3 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | trial with a planned duration of 5 years. Patients with the common forms of RP are assigned to either a test or a control group. All receive 15,000 IU/day of vitamin A palmitate in addition to either 1200 mg/d of docosahexaenoic acid or control capsules. Participants will not know the contents of the supplement or the ... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. trial with a planned duration of 5 years. Patients with the common forms of RP are assigned to either a test or a control group. All receive 15,000 IU/day of vitamin A palmitate in addition to either 1200 mg/d of docosahexaenoic acid or cont... |
NCT00000116_4 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | Primary purpose is TREATMENT. Masking info details: Masking is QUADRUPLE. Masking description is In this trial neither the participants, nor the clinicians, nor the investigators were aware of treatment group assignment. Who masked includes PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR. Enrollment info de... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. Primary purpose is TREATMENT. Masking info details: Masking is QUADRUPLE. Masking description is In this trial neither the participants, nor the clinicians, nor the investigators were aware of treatment group assignment. Who masked includes ... |
NCT00000116_5 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | Patients randomized to this arm received 500 mg/d of fatty acid with no docosahexaenoic acid and 15000 IU/ Vitamin A as retinyl palmitate. Intervention names includes Dietary Supplement: Vitamin A, Dietary Supplement: Control fatty acid. Interventions includes Type is DIETARY_SUPPLEMENT. Name is Vitamin A. Description ... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. Patients randomized to this arm received 500 mg/d of fatty acid with no docosahexaenoic acid and 15000 IU/ Vitamin A as retinyl palmitate. Intervention names includes Dietary Supplement: Vitamin A, Dietary Supplement: Control fatty acid. Int... |
NCT00000116_6 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | (HFA) total point score 30-2 program. Description is Sum of points in Decibels of total points seen in 30-2 program. Higher scores = better vision/larger visual field. Time frame is Annual percent change per year at each of 4 years of followup. Secondary outcomes includes Measure is Change in Humphrey Field Analyzer (H... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. (HFA) total point score 30-2 program. Description is Sum of points in Decibels of total points seen in 30-2 program. Higher scores = better vision/larger visual field. Time frame is Annual percent change per year at each of 4 years of follow... |
NCT00000116_7 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | change per year at each of four years of followup, Measure is Change in Early Treatment of Diabetic Retinopathy(EDTRS) Visual Acuity. Description is Number of letters read per year. More letters read = better visual acuity. Time frame is Change in number of letters read per year at each of four years of followup. Eligi... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. change per year at each of four years of followup, Measure is Change in Early Treatment of Diabetic Retinopathy(EDTRS) Visual Acuity. Description is Number of letters read per year. More letters read = better visual acuity. Time frame is Cha... |
NCT00000116_8 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | LE 10,000 IU/d Supplement intake LE 5000 IU/d of Vitamin A and LE 30 IU/d Vitamin E Consumption LE 3 alcoholic beverages per day Medical and other criteria: Body Mass Index Less than (LT )40 and weight GE 5th percentile for age, sex, and height Serum retinol level LE 100 mg/dl and serum retinyl ester levels LE 380 nm/L... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. LE 10,000 IU/d Supplement intake LE 5000 IU/d of Vitamin A and LE 30 IU/d Vitamin E Consumption LE 3 alcoholic beverages per day Medical and other criteria: Body Mass Index Less than (LT )40 and weight GE 5th percentile for age, sex, and hei... |
NCT00000116_9 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | metabolism of DHA or Vitamin A. Healthy volunteers is True. Sex is ALL. Minimum age is 18 Years. Maximum age is 55 Years. Std ages includes ADULT. Contacts locations module details: Overall officials includes Name is Eliot Berson (Deceased), MD. Affiliation is Berman-Gund Laboratory for the Study of Retinal Degeneratio... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. metabolism of DHA or Vitamin A. Healthy volunteers is True. Sex is ALL. Minimum age is 18 Years. Maximum age is 55 Years. Std ages includes ADULT. Contacts locations module details: Overall officials includes Name is Eliot Berson (Deceased),... |
NCT00000116_10 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett W. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993 Jun;111(6):761-72. doi: 10.1001/archopht.1993.01090060049022, Pmid is 15364708. Type is RESULT. Citation is Berson EL, Rosner B, Sandberg MA, Weigel-DiF... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett W. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993 Jun;111(6):761-72. doi: 10.1001/archopht.1993.01090060049022, Pmid is 153... |
NCT00000116_11 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | WC, Schaefer EJ. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004 Sep;122(9):1306-14. doi: 10.1001/archopht.122.9.1306. Derived section details: Misc info module details: Version holder is 2025-03-28. Condition brows... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. WC, Schaefer EJ. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004 Sep;122(9):1306-14. doi: 10.1001/archopht.122.9.1306. Derived section d... |
NCT00000116_12 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | Relevance is HIGH, Id is M15009. Name is Retinitis Pigmentosa. As found is Retinitis Pigmentosa. Relevance is HIGH, Id is M14999. Name is Retinal Diseases. Relevance is LOW, Id is M8271. Name is Eye Diseases. Relevance is LOW, Id is M18339. Name is Eye Diseases, Hereditary. Relevance is LOW, Id is M29107. Name is Retin... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. Relevance is HIGH, Id is M15009. Name is Retinitis Pigmentosa. As found is Retinitis Pigmentosa. Relevance is HIGH, Id is M14999. Name is Retinal Diseases. Relevance is LOW, Id is M8271. Name is Eye Diseases. Relevance is LOW, Id is M18339. ... |
NCT00000116_13 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | Intervention browse module details: Meshes includes Id is D014801. Term is Vitamin A. Ancestors includes Id is D014815. Term is Vitamins, Id is D018977. Term is Micronutrients, Id is D045505. Term is Physiological Effects of Drugs. Browse leaves includes Id is M17550. Name is Vitamin D. Relevance is LOW, Id is M17558. ... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. Intervention browse module details: Meshes includes Id is D014801. Term is Vitamin A. Ancestors includes Id is D014815. Term is Vitamins, Id is D018977. Term is Micronutrients, Id is D045505. Term is Physiological Effects of Drugs. Browse le... |
NCT00000116_14 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | T468. Name is Vitamin A. As found is Allows. Relevance is HIGH. Browse branches includes Abbrev is BDCA. Name is Bone Density Conservation Agents, Abbrev is Micro. Name is Micronutrients, Abbrev is All. Name is All Drugs and Chemicals, Abbrev is ANeo. Name is Antineoplastic Agents, Abbrev is Vi. Name is Vitamins, Abbre... | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A. T468. Name is Vitamin A. As found is Allows. Relevance is HIGH. Browse branches includes Abbrev is BDCA. Name is Bone Density Conservation Agents, Abbrev is Micro. Name is Micronutrients, Abbrev is All. Name is All Drugs and Chemicals, Abbre... |
NCT00000117_0 | Intravenous Immunoglobulin Therapy in Optic Neuritis | Protocol section details: Identification module details: Nct id is NCT00000117. Org study id info details: Id is NEI-13. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Intravenous Immunoglobulin Therapy in Optic Neuritis. Status module details: Status verified date is 2009... | Intravenous Immunoglobulin Therapy in Optic Neuritis. Protocol section details: Identification module details: Nct id is NCT00000117. Org study id info details: Id is NEI-13. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Intravenous Immunoglobulin Therapy in Optic Neuriti... |
NCT00000117_1 | Intravenous Immunoglobulin Therapy in Optic Neuritis | Sponsor collaborators module details: Lead sponsor details: Name is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis... | Intravenous Immunoglobulin Therapy in Optic Neuritis. Sponsor collaborators module details: Lead sponsor details: Name is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring ... |
NCT00000117_2 | Intravenous Immunoglobulin Therapy in Optic Neuritis | Characteristically, patients present with central visual loss that peaks within a few days and is often associated with eye pain. Visual loss may be complete. Spontaneous recovery usually begins within 4 weeks, and marked recovery occurs within 1 to 3 months in most patients. Although clinical improvement is the rule, ... | Intravenous Immunoglobulin Therapy in Optic Neuritis. Characteristically, patients present with central visual loss that peaks within a few days and is often associated with eye pain. Visual loss may be complete. Spontaneous recovery usually begins within 4 weeks, and marked recovery occurs within 1 to 3 months in most... |
NCT00000117_3 | Intravenous Immunoglobulin Therapy in Optic Neuritis | and, later, oligodendrocyte loss, axonal loss, and gliosis. Remyelination by oligodendrocytes occurs early in the MS lesion, as documented by myelin sheaths that are abnormally thin relative to axon diameter. These thin myelin sheaths are often seen prominently at the edge of demyelinated plaques. A recent series of st... | Intravenous Immunoglobulin Therapy in Optic Neuritis. and, later, oligodendrocyte loss, axonal loss, and gliosis. Remyelination by oligodendrocytes occurs early in the MS lesion, as documented by myelin sheaths that are abnormally thin relative to axon diameter. These thin myelin sheaths are often seen prominently at t... |
NCT00000117_4 | Intravenous Immunoglobulin Therapy in Optic Neuritis | could be used to improve clinical recovery in ON and MS. Work at the Mayo Clinic, has shown that both immunoglobulin G (IgG) directed against spinal cord antigens and purified polyclonal mouse IgG administered systemically promote extensive remyelination in SJL mice chronically infected with Theiler's virus. In additio... | Intravenous Immunoglobulin Therapy in Optic Neuritis. could be used to improve clinical recovery in ON and MS. Work at the Mayo Clinic, has shown that both immunoglobulin G (IgG) directed against spinal cord antigens and purified polyclonal mouse IgG administered systemically promote extensive remyelination in SJL mice... |
NCT00000117_5 | Intravenous Immunoglobulin Therapy in Optic Neuritis | proliferation or differentiation of these cells. In a preliminary, open-label pilot study of patients with chronic, steroid-unresponsive ON, Drs. van Engelen, Hommes, and colleagues suggested that improvement in visual recovery could be seen following IgG treatment in patients with chronic, stable ON. These encouraging... | Intravenous Immunoglobulin Therapy in Optic Neuritis. proliferation or differentiation of these cells. In a preliminary, open-label pilot study of patients with chronic, steroid-unresponsive ON, Drs. van Engelen, Hommes, and colleagues suggested that improvement in visual recovery could be seen following IgG treatment ... |
NCT00000117_6 | Intravenous Immunoglobulin Therapy in Optic Neuritis | meet the inclusion criteria needed to have a stable loss of visual function (unchanged between the pre-enrollment screening visit and the enrollment visit). All patients wre re-examined at 3, 6, 9, and 12 months, with the primary outcome being the impact of treatment on visual acuity at 6 months as determined by measur... | Intravenous Immunoglobulin Therapy in Optic Neuritis. meet the inclusion criteria needed to have a stable loss of visual function (unchanged between the pre-enrollment screening visit and the enrollment visit). All patients wre re-examined at 3, 6, 9, and 12 months, with the primary outcome being the impact of treatmen... |
NCT00000117_7 | Intravenous Immunoglobulin Therapy in Optic Neuritis | acuity by an average of 0.2 at 6 months. The secondary outcome measures included change in visual acuity at 3, 9, and 12 months, as determined on a retroilluminated ETDRS chart at 4 meters; change in visual fields at 6 and 12 months; change in visual evoked responses at 3, 6, and 12 months; and change in neurological e... | Intravenous Immunoglobulin Therapy in Optic Neuritis. acuity by an average of 0.2 at 6 months. The secondary outcome measures included change in visual acuity at 3, 9, and 12 months, as determined on a retroilluminated ETDRS chart at 4 meters; change in visual fields at 6 and 12 months; change in visual evoked response... |
NCT00000117_8 | Intravenous Immunoglobulin Therapy in Optic Neuritis | patients must have a history of one or more episodes of previous demyelinating optic neuritis occurring in the setting of classic, adult-onset definite MS (clinically definite or laboratory-supported definite MS, or cranial MRI changes consistent with MS). In most cases, onset of MS will have occurred between the ages ... | Intravenous Immunoglobulin Therapy in Optic Neuritis. patients must have a history of one or more episodes of previous demyelinating optic neuritis occurring in the setting of classic, adult-onset definite MS (clinically definite or laboratory-supported definite MS, or cranial MRI changes consistent with MS). In most c... |
NCT00000117_9 | Intravenous Immunoglobulin Therapy in Optic Neuritis | least 1 month) in the Department of Ophthalmology at the Mayo Clinic. Optic disc pallor must be present. Patients must have impairment in the affected eye(s) on perimetry consistent with optic nerve dysfunction and must have a visual field mean deviation of less than -4.00. Patients must not have received ACTH or corti... | Intravenous Immunoglobulin Therapy in Optic Neuritis. least 1 month) in the Department of Ophthalmology at the Mayo Clinic. Optic disc pallor must be present. Patients must have impairment in the affected eye(s) on perimetry consistent with optic nerve dysfunction and must have a visual field mean deviation of less tha... |
NCT00000117_10 | Intravenous Immunoglobulin Therapy in Optic Neuritis | section details: Misc info module details: Version holder is 2025-03-28. Condition browse module details: Meshes includes Id is D009443. Term is Neuritis, Id is D009902. Term is Optic Neuritis. Ancestors includes Id is D010523. Term is Peripheral Nervous System Diseases, Id is D009468. Term is Neuromuscular Diseases, I... | Intravenous Immunoglobulin Therapy in Optic Neuritis. section details: Misc info module details: Version holder is 2025-03-28. Condition browse module details: Meshes includes Id is D009443. Term is Neuritis, Id is D009902. Term is Optic Neuritis. Ancestors includes Id is D010523. Term is Peripheral Nervous System Dise... |
NCT00000117_11 | Intravenous Immunoglobulin Therapy in Optic Neuritis | Relevance is LOW, Id is M12832. Name is Optic Nerve Diseases. Relevance is LOW, Id is M6605. Name is Cranial Nerve Diseases. Relevance is LOW, Id is M8271. Name is Eye Diseases. Relevance is LOW, Id is T4263. Name is Optic Neuritis. As found is Optic Neuritis. Relevance is HIGH. Browse branches includes Abbrev is BC10.... | Intravenous Immunoglobulin Therapy in Optic Neuritis. Relevance is LOW, Id is M12832. Name is Optic Nerve Diseases. Relevance is LOW, Id is M6605. Name is Cranial Nerve Diseases. Relevance is LOW, Id is M8271. Name is Eye Diseases. Relevance is LOW, Id is T4263. Name is Optic Neuritis. As found is Optic Neuritis. Relev... |
NCT00000117_12 | Intravenous Immunoglobulin Therapy in Optic Neuritis | Name is Immunoglobulins, Intravenous. As found is Posterior. Relevance is HIGH, Id is M8836. Name is gamma-Globulins. Relevance is LOW, Id is M20191. Name is Rho(D) Immune Globulin. Relevance is LOW, Id is M10184. Name is Immunoglobulins. As found is Posterior. Relevance is HIGH, Id is M4225. Name is Antibodies. As fou... | Intravenous Immunoglobulin Therapy in Optic Neuritis. Name is Immunoglobulins, Intravenous. As found is Posterior. Relevance is HIGH, Id is M8836. Name is gamma-Globulins. Relevance is LOW, Id is M20191. Name is Rho(D) Immune Globulin. Relevance is LOW, Id is M10184. Name is Immunoglobulins. As found is Posterior. Rele... |
NCT00000118_0 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Protocol section details: Identification module details: Nct id is NCT00000118. Org study id info details: Id is NEI-14. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Ganciclovir Implant Study for Cytomegalovirus Retinitis. Status module details: Status verified date is 2... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Protocol section details: Identification module details: Nct id is NCT00000118. Org study id info details: Id is NEI-14. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Ganciclovir Implant Study for Cytomegalovirus Re... |
NCT00000118_1 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Sponsor collaborators module details: Lead sponsor details: Name is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To determine the therapeutic efficacy of a sustained-release intraocular drug delivery system for ganciclovir therapy of cytomegalovirus (CMV) retinitis in patient... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Sponsor collaborators module details: Lead sponsor details: Name is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To determine the therapeutic efficacy of a sustained-release intraocular drug delivery system for ganciclo... |
NCT00000118_2 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Unfortunately, CMV retinitis usually progresses despite daily maintenance therapy, and both drugs are associated with significant systemic toxicity that often limits their therapeutic usefulness. As an alternative to intravenous administration, direct intravitreal injections of ganciclovir have been studied and have be... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Unfortunately, CMV retinitis usually progresses despite daily maintenance therapy, and both drugs are associated with significant systemic toxicity that often limits their therapeutic usefulness. As an alternative to intravenous administration, direct intravitrea... |
NCT00000118_3 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | device consists of a 6-mg pellet of ganciclovir that is coated with a series of polymers with variable permeability to ganciclovir. The device is surgically implanted through the pars plana. Thirty eyes of 26 patients with unilateral non-sight-threatening CMV retinitis were randomly assigned to one of two groups: (1) i... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. device consists of a 6-mg pellet of ganciclovir that is coated with a series of polymers with variable permeability to ganciclovir. The device is surgically implanted through the pars plana. Thirty eyes of 26 patients with unilateral non-sight-threatening CMV ret... |
NCT00000118_4 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | two patients.) Patients assigned to immediate treatment underwent surgery to implant the ganciclovir device within 48 hours of enrollment and baseline photographs. Postoperatively, patients were evaluated the next day, weekly for 2 weeks, and then every 2 weeks until progression of CMV retinitis occurred. At each exami... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. two patients.) Patients assigned to immediate treatment underwent surgery to implant the ganciclovir device within 48 hours of enrollment and baseline photographs. Postoperatively, patients were evaluated the next day, weekly for 2 weeks, and then every 2 weeks u... |
NCT00000118_5 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | The ganciclovir implant was exchanged at 32 weeks or earlier if progression of CMV retinitis occurred. The primary end point was time to CMV retinitis progression, defined as the time (days) from initiating therapy until the advancement of 750-um over a 750 um front of any border of any lesion was observed. Standardize... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. The ganciclovir implant was exchanged at 32 weeks or earlier if progression of CMV retinitis occurred. The primary end point was time to CMV retinitis progression, defined as the time (days) from initiating therapy until the advancement of 750-um over a 750 um fr... |
NCT00000118_6 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Study type is INTERVENTIONAL. Phases includes PHASE3. Design info details: Allocation is RANDOMIZED. Primary purpose is TREATMENT. Arms interventions module details: Interventions includes Type is DEVICE. Name is Sustained-Release Intraocular Drug Delivery System. Eligibility module details: Eligibility criteria is All... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Study type is INTERVENTIONAL. Phases includes PHASE3. Design info details: Allocation is RANDOMIZED. Primary purpose is TREATMENT. Arms interventions module details: Interventions includes Type is DEVICE. Name is Sustained-Release Intraocular Drug Delivery System... |
NCT00000118_7 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | module details: References includes Pmid is 7993207. Type is BACKGROUND. Citation is Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, Chew EY, Ashton P, Davis MD, Nussenblatt RB. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled cl... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. module details: References includes Pmid is 7993207. Type is BACKGROUND. Citation is Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, Chew EY, Ashton P, Davis MD, Nussenblatt RB. Treatment of cytomegalovirus retinitis with an intraocular sustaine... |
NCT00000118_8 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Id is D000086982. Term is Blood-Borne Infections, Id is D003141. Term is Communicable Diseases, Id is D007239. Term is Infections, Id is D015229. Term is Sexually Transmitted Diseases, Viral, Id is D012749. Term is Sexually Transmitted Diseases, Id is D016180. Term is Lentivirus Infections, Id is D012192. Term is Retro... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Id is D000086982. Term is Blood-Borne Infections, Id is D003141. Term is Communicable Diseases, Id is D007239. Term is Infections, Id is D015229. Term is Sexually Transmitted Diseases, Viral, Id is D012749. Term is Sexually Transmitted Diseases, Id is D016180. Te... |
NCT00000118_9 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Infections, Id is D006566. Term is Herpesviridae Infections, Id is D004266. Term is DNA Virus Infections. Browse leaves includes Id is M16355. Name is Syndrome. Relevance is LOW, Id is M10283. Name is Infections. Relevance is LOW, Id is M6368. Name is Communicable Diseases. Relevance is LOW, Id is M10199. Name is Immun... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Infections, Id is D006566. Term is Herpesviridae Infections, Id is D004266. Term is DNA Virus Infections. Browse leaves includes Id is M16355. Name is Syndrome. Relevance is LOW, Id is M10283. Name is Infections. Relevance is LOW, Id is M6368. Name is Communicabl... |
NCT00000118_10 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Relevance is HIGH, Id is M2593. Name is Blood-Borne Infections. Relevance is LOW, Id is M15558. Name is Sexually Transmitted Diseases. Relevance is LOW, Id is M17933. Name is Sexually Transmitted Diseases, Viral. Relevance is LOW, Id is M18640. Name is Lentivirus Infections. Relevance is LOW, Id is M15026. Name is Retr... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Relevance is HIGH, Id is M2593. Name is Blood-Borne Infections. Relevance is LOW, Id is M15558. Name is Sexually Transmitted Diseases. Relevance is LOW, Id is M17933. Name is Sexually Transmitted Diseases, Viral. Relevance is LOW, Id is M18640. Name is Lentivirus... |
NCT00000118_11 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Diseases. Relevance is LOW, Id is M18371. Name is Eye Infections. Relevance is LOW, Id is M18382. Name is Eye Infections, Viral. Relevance is LOW, Id is M6791. Name is Cytomegalovirus Infections. Relevance is LOW, Id is M9643. Name is Herpesviridae Infections. Relevance is LOW, Id is M7442. Name is DNA Virus Infections... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Diseases. Relevance is LOW, Id is M18371. Name is Eye Infections. Relevance is LOW, Id is M18382. Name is Eye Infections, Viral. Relevance is LOW, Id is M6791. Name is Cytomegalovirus Infections. Relevance is LOW, Id is M9643. Name is Herpesviridae Infections. Re... |
NCT00000118_12 | Ganciclovir Implant Study for Cytomegalovirus Retinitis | Sexual Organs, and Pregnancy Conditions, Abbrev is Rare. Name is Rare Diseases. Intervention browse module details: Browse leaves includes Id is M18331. Name is Ganciclovir. Relevance is LOW, Id is M340476. Name is Ganciclovir triphosphate. Relevance is LOW. Browse branches includes Abbrev is Infe. Name is Anti-Infecti... | Ganciclovir Implant Study for Cytomegalovirus Retinitis. Sexual Organs, and Pregnancy Conditions, Abbrev is Rare. Name is Rare Diseases. Intervention browse module details: Browse leaves includes Id is M18331. Name is Ganciclovir. Relevance is LOW, Id is M340476. Name is Ganciclovir triphosphate. Relevance is LOW. Brow... |
NCT00000120_0 | Clinical Trial of Eye Prophylaxis in the Newborn | Protocol section details: Identification module details: Nct id is NCT00000120. Org study id info details: Id is NEI-19. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Clinical Trial of Eye Prophylaxis in the Newborn. Status module details: Status verified date is 2009-09.... | Clinical Trial of Eye Prophylaxis in the Newborn. Protocol section details: Identification module details: Nct id is NCT00000120. Org study id info details: Id is NEI-19. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is Clinical Trial of Eye Prophylaxis in the Newborn. Statu... |
NCT00000120_1 | Clinical Trial of Eye Prophylaxis in the Newborn | is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To compare the effectiveness of silver nitrate drops, erythromycin ointment, or no medication in preventing neonatal conjunctivitis caused by Chlamydia trachomatis and other eye infections. To compare side effects of the two pro... | Clinical Trial of Eye Prophylaxis in the Newborn. is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To compare the effectiveness of silver nitrate drops, erythromycin ointment, or no medication in preventing neonatal conjunctivitis caused by Chlamydia trachomatis and other eye ... |
NCT00000120_2 | Clinical Trial of Eye Prophylaxis in the Newborn | of three treatments is presently required by law to help prevent gonorrheal eye infection in newborn babies: 1 percent silver nitrate drops, erythromycin ointment, or tetracycline ointment. Although all three treatments appear to prevent eye infections from gonorrhea, silver nitrate and erythromycin may also partially ... | Clinical Trial of Eye Prophylaxis in the Newborn. of three treatments is presently required by law to help prevent gonorrheal eye infection in newborn babies: 1 percent silver nitrate drops, erythromycin ointment, or tetracycline ointment. Although all three treatments appear to prevent eye infections from gonorrhea, s... |
NCT00000120_3 | Clinical Trial of Eye Prophylaxis in the Newborn | Moreover, Great Britain, which used no eye prophylactic agents for newborns for the 25 years preceding the study, has rates of neonatal conjunctivitis similar to those in the United States. For these reasons, the Washington State Board of Health granted this study an exemption from the State law to allow the investigat... | Clinical Trial of Eye Prophylaxis in the Newborn. Moreover, Great Britain, which used no eye prophylactic agents for newborns for the 25 years preceding the study, has rates of neonatal conjunctivitis similar to those in the United States. For these reasons, the Washington State Board of Health granted this study an ex... |
NCT00000120_4 | Clinical Trial of Eye Prophylaxis in the Newborn | United States for ocular prophylaxis.) Women were recruited from the University of Washington Medical Center-associated obstetric units. Among the 2,577 women eligible for possible participation, 758 enrolled. Of these participants, 89 were not randomized. Among the 669 randomized women, 39 were not available for perso... | Clinical Trial of Eye Prophylaxis in the Newborn. United States for ocular prophylaxis.) Women were recruited from the University of Washington Medical Center-associated obstetric units. Among the 2,577 women eligible for possible participation, 758 enrolled. Of these participants, 89 were not randomized. Among the 669... |
NCT00000120_5 | Clinical Trial of Eye Prophylaxis in the Newborn | the etiology of the conjunctivitis and to find nasolacrimal duct obstruction. Conditions module details: Conditions includes Chlamydia Infections, Ophthalmia Neonatorum. Keywords includes Neonatal Conjunctivitis. Design module details: Study type is INTERVENTIONAL. Phases includes PHASE3. Design info details: Allocatio... | Clinical Trial of Eye Prophylaxis in the Newborn. the etiology of the conjunctivitis and to find nasolacrimal duct obstruction. Conditions module details: Conditions includes Chlamydia Infections, Ophthalmia Neonatorum. Keywords includes Neonatal Conjunctivitis. Design module details: Study type is INTERVENTIONAL. Phas... |
NCT00000120_6 | Clinical Trial of Eye Prophylaxis in the Newborn | they planned to stay at the hospital at least 48 hours following delivery and lived in the greater Seattle metropolitan area. Infants were eligible whether they were delivered vaginally or by cesarean section. Excluded from the study were siblings of infants enrolled in the study, women who were culture-positive for go... | Clinical Trial of Eye Prophylaxis in the Newborn. they planned to stay at the hospital at least 48 hours following delivery and lived in the greater Seattle metropolitan area. Infants were eligible whether they were delivered vaginally or by cesarean section. Excluded from the study were siblings of infants enrolled in... |
NCT00000120_7 | Clinical Trial of Eye Prophylaxis in the Newborn | Eye Prophylaxis Study Group. Am J Epidemiol. 1993 Sep 1;138(5):326-32. doi: 10.1093/oxfordjournals.aje.a116862, Pmid is 8233733. Type is BACKGROUND. Citation is Bell TA, Grayston JT, Krohn MA, Kronmal RA. Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among... | Clinical Trial of Eye Prophylaxis in the Newborn. Eye Prophylaxis Study Group. Am J Epidemiol. 1993 Sep 1;138(5):326-32. doi: 10.1093/oxfordjournals.aje.a116862, Pmid is 8233733. Type is BACKGROUND. Citation is Bell TA, Grayston JT, Krohn MA, Kronmal RA. Randomized trial of silver nitrate, erythromycin, and no eye prop... |
NCT00000120_8 | Clinical Trial of Eye Prophylaxis in the Newborn | is Bacterial Infections, Id is D001423. Term is Bacterial Infections and Mycoses, Id is D007239. Term is Infections, Id is D015231. Term is Sexually Transmitted Diseases, Bacterial, Id is D012749. Term is Sexually Transmitted Diseases, Id is D003141. Term is Communicable Diseases, Id is D000091662. Term is Genital Dise... | Clinical Trial of Eye Prophylaxis in the Newborn. is Bacterial Infections, Id is D001423. Term is Bacterial Infections and Mycoses, Id is D007239. Term is Infections, Id is D015231. Term is Sexually Transmitted Diseases, Bacterial, Id is D012749. Term is Sexually Transmitted Diseases, Id is D003141. Term is Communicabl... |
NCT00000120_9 | Clinical Trial of Eye Prophylaxis in the Newborn | Relevance is LOW, Id is M6368. Name is Communicable Diseases. Relevance is LOW, Id is M5934. Name is Chlamydia Infections. As found is Chlamydia Infections. Relevance is HIGH, Id is M6455. Name is Conjunctivitis. Relevance is LOW, Id is M12808. Name is Endophthalmitis. Relevance is LOW, Id is M12809. Name is Ophthalmia... | Clinical Trial of Eye Prophylaxis in the Newborn. Relevance is LOW, Id is M6368. Name is Communicable Diseases. Relevance is LOW, Id is M5934. Name is Chlamydia Infections. As found is Chlamydia Infections. Relevance is HIGH, Id is M6455. Name is Conjunctivitis. Relevance is LOW, Id is M12808. Name is Endophthalmitis. ... |
NCT00000120_10 | Clinical Trial of Eye Prophylaxis in the Newborn | Id is M2876. Name is Genital Diseases. Relevance is LOW, Id is M2875. Name is Urogenital Diseases. Relevance is LOW, Id is M18371. Name is Eye Infections. Relevance is LOW, Id is M8271. Name is Eye Diseases. Relevance is LOW, Id is M6458. Name is Conjunctivitis, Bacterial. Relevance is LOW, Id is M18372. Name is Eye In... | Clinical Trial of Eye Prophylaxis in the Newborn. Id is M2876. Name is Genital Diseases. Relevance is LOW, Id is M2875. Name is Urogenital Diseases. Relevance is LOW, Id is M18371. Name is Eye Infections. Relevance is LOW, Id is M8271. Name is Eye Diseases. Relevance is LOW, Id is M6458. Name is Conjunctivitis, Bacteri... |
NCT00000120_11 | Clinical Trial of Eye Prophylaxis in the Newborn | Pathology, Abbrev is BXS. Name is Urinary Tract, Sexual Organs, and Pregnancy Conditions, Abbrev is BC11. Name is Eye Diseases, Abbrev is BC16. Name is Diseases and Abnormalities at or Before Birth, Abbrev is Rare. Name is Rare Diseases. Intervention browse module details: Meshes includes Id is D004917. Term is Erythro... | Clinical Trial of Eye Prophylaxis in the Newborn. Pathology, Abbrev is BXS. Name is Urinary Tract, Sexual Organs, and Pregnancy Conditions, Abbrev is BC11. Name is Eye Diseases, Abbrev is BC16. Name is Diseases and Abnormalities at or Before Birth, Abbrev is Rare. Name is Rare Diseases. Intervention browse module detai... |
NCT00000120_12 | Clinical Trial of Eye Prophylaxis in the Newborn | Mechanisms of Pharmacological Action, Id is D000891. Term is Anti-Infective Agents, Local. Browse leaves includes Id is M15640. Name is Silver Nitrate. As found is Zofran. Relevance is HIGH, Id is M8068. Name is Erythromycin. As found is Excipients. Relevance is HIGH, Id is M8069. Name is Erythromycin Estolate. As foun... | Clinical Trial of Eye Prophylaxis in the Newborn. Mechanisms of Pharmacological Action, Id is D000891. Term is Anti-Infective Agents, Local. Browse leaves includes Id is M15640. Name is Silver Nitrate. As found is Zofran. Relevance is HIGH, Id is M8068. Name is Erythromycin. As found is Excipients. Relevance is HIGH, I... |
NCT00000120_13 | Clinical Trial of Eye Prophylaxis in the Newborn | Name is Anti-Infective Agents, Local. Relevance is LOW. Browse branches includes Abbrev is Infe. Name is Anti-Infective Agents, Abbrev is All. Name is All Drugs and Chemicals, Abbrev is Gast. Name is Gastrointestinal Agents. Has results is False. | Clinical Trial of Eye Prophylaxis in the Newborn. Name is Anti-Infective Agents, Local. Relevance is LOW. Browse branches includes Abbrev is Infe. Name is Anti-Infective Agents, Abbrev is All. Name is All Drugs and Chemicals, Abbrev is Gast. Name is Gastrointestinal Agents. Has results is False. |
NCT00000121_0 | The Prism Adaptation Study (PAS) | Protocol section details: Identification module details: Nct id is NCT00000121. Org study id info details: Id is NEI-20. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is The Prism Adaptation Study (PAS). Status module details: Status verified date is 2009-09. Overall status ... | The Prism Adaptation Study (PAS). Protocol section details: Identification module details: Nct id is NCT00000121. Org study id info details: Id is NEI-20. Organization details: Full name is National Eye Institute (NEI). Class is NIH. Brief title is The Prism Adaptation Study (PAS). Status module details: Status verifie... |
NCT00000121_1 | The Prism Adaptation Study (PAS) | details: Lead sponsor details: Name is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To determine whether the preoperative use of prisms in eyeglasses can improve the outcome of surgery for acquired esotropia, a type of strabismus. To determine whether patients who respond to ... | The Prism Adaptation Study (PAS). details: Lead sponsor details: Name is National Eye Institute (NEI). Class is NIH. Description module details: Brief summary is To determine whether the preoperative use of prisms in eyeglasses can improve the outcome of surgery for acquired esotropia, a type of strabismus. To determin... |
NCT00000121_2 | The Prism Adaptation Study (PAS) | error) in predicting which patients are more likely to benefit from prism adaptation. Detailed description is Acquired esotropia (crossed eyes that develop after a child reaches the age of 6 months) accounts for 25 percent of all patients with misaligned eyes. Surgery to correct esotropia is done primarily to attain fu... | The Prism Adaptation Study (PAS). error) in predicting which patients are more likely to benefit from prism adaptation. Detailed description is Acquired esotropia (crossed eyes that develop after a child reaches the age of 6 months) accounts for 25 percent of all patients with misaligned eyes. Surgery to correct esotro... |
NCT00000121_3 | The Prism Adaptation Study (PAS) | studies pointed to the need for a multicenter, randomized, controlled clinical trial designed to prove or disprove scientifically the beneficial effect of prisms. The Prism Adaptation Study was a double randomization trial involving 286 patients. Three-fifths of the patients were randomly selected for prism adaptation ... | The Prism Adaptation Study (PAS). studies pointed to the need for a multicenter, randomized, controlled clinical trial designed to prove or disprove scientifically the beneficial effect of prisms. The Prism Adaptation Study was a double randomization trial involving 286 patients. Three-fifths of the patients were rando... |
NCT00000121_4 | The Prism Adaptation Study (PAS) | at 1 week, 1 month, 3 months, 6 months, and 1 year. An independent examiner, masked to the treatment assignment, evaluated the patient at the 6-month followup. The results were analyzed to determine whether the outcome was better in patients who underwent prism adaptation or in those who underwent conventional treatmen... | The Prism Adaptation Study (PAS). at 1 week, 1 month, 3 months, 6 months, and 1 year. An independent examiner, masked to the treatment assignment, evaluated the patient at the 6-month followup. The results were analyzed to determine whether the outcome was better in patients who underwent prism adaptation or in those w... |
YAML Metadata Warning:empty or missing yaml metadata in repo card
Check out the documentation for more information.
Special Notice
For this dataset, we open-source our processed clinical trial records from ClinicalTrials.gov, filtering for studies that had completed recruitment and were classified as Phase 3 or Phase 4, or that investigated device-based or behavioral interventions. This selection yielded $156,887$ trials as of March 2025.
Agentic Medical RAG
Agentic Memory-augmented Retrieval and Evidence Grounding in Medicine
π Announcements
[2026.06.01]
Our Agentic Medical RAG manuscript is published in International Journal of Medical Informatics. Link to the paper and Supplementary Material.
π Table of contents
- Agentic medical RAG
- Installation
- Quick start
- Prompt format
- Toolkit description
- Dataset description
- Benchmarks and results
- Real-world deployment
- Algorithm
- Structure of the code
- Citation
- Contact
- Contributions
- Acknowledgements
Agentic medical RAG
We developed a unified, open-source LLM-based agentic system that integrates document retrieval, re-ranking, evidence grounding, and diagnosis generation to support dynamic, multi-step medical reasoning.
Our system features a lightweight retrieval-augmented generation pipeline coupled with a cache-and-prune memory bank, enabling efficient long-context inference beyond standard LLM limits.
The system autonomously invokes specialized tools, eliminating the need for manual prompt engineering or brittle multi-stage templates.
π» Installation
At the time, this work was conducted using 4 NVIDIA L40S GPUs. To facilitate package installation and dependency configuration, we validated our agentic system on 2 NVIDIA RTX PRO 6000 Blackwell GPUs running CUDA 13.2 and 0.17.0+cu132.
Please NOTE that our vLLM installation is built from source instead of direct pip install.
First, create a Python 3.10 environment (higher versions should work as well), then
pip install -r requirements.txt
Then, the most important part is to install/compile vLLM:
- Manually download the vLLM 0.17.0 source code from https://github.com/vllm-project/vllm/releases/tag/v0.17.0.
tar -xvzf vllm-0.17.0.tar.gzpip install --editable vllm-0.17.0 --no-cache-dir
Then, the vLLM will be compiled from source and installed. Other vLLM versions (e.g., 0.6.3), can also be compiled in this way.
To set up the Transformers and Triton saving path, run the following commands in your terminal:
For example, if your path is /projectnb/vkolagrp/:
export TRANSFORMERS_CACHE=/projectnb/vkolagrp/.cache
export HF_HOME=/projectnb/vkolagrp/.cache
export HF_DATASETS_CACHE=/projectnb/vkolagrp/.cache
export TRITON_CACHE_DIR=/projectnb/vkolagrp/.cache/.triton
Please change /projectnb/vkolagrp/ to your own path. After running the commands, all your Transformers models and datasets will be saved in the paths you defined.
π Quick start
We use a two-stage retrieval pipeline:
- Document retrieval: SPECTER performs coarse-grained semantic search over each evidence source and retrieves the top-K candidate documents.
- Evidence reranking: gte-Qwen2-7B-instruct computes fine-grained queryβdocument similarity and selects the top-R most relevant documents for downstream evidence grounding and medical reasoning.
By default, the system retrieves $32$ candidates from each of the six sources, producing $192$ candidates in total, and reranks them to retain the $32$ most relevant documents. This multi-source design provides complementary evidence from biomedical literature, clinical studies, textbooks, case reports, and general medical knowledge.
Retrieval
The retrieval module identifies clinically relevant evidence from six medical and scientific sources:
- PubMed abstracts
- PubMed Central full-text articles
- Medical textbooks
- ClinicalTrials.gov records
- Wikipedia articles
- New England Journal of Medicine (NEJM) clinical case reports
Due to copyright restrictions, the NEJM clinical case report dataset is not included in this open-source release.
To retrieve documents for all supported benchmarks, run:
sh run_retrieve.sh
To retrieve documents for a specific benchmark, run the corresponding command:
python retrieve.py --benchmark USMLE_STEP_1 --save_folder "RETRIEVED_USMLE_STEP_1"
python retrieve.py --benchmark USMLE_STEP_2 --save_folder "RETRIEVED_USMLE_STEP_2"
python retrieve.py --benchmark USMLE_STEP_3 --save_folder "RETRIEVED_USMLE_STEP_3"
python retrieve.py --benchmark MedQA --save_folder "RETRIEVED_MedQA"
python retrieve.py --benchmark MedExpQA --save_folder "RETRIEVED_MedExpQA"
python retrieve.py --benchmark PubMedQA --save_folder "RETRIEVED_PubMedQA"
Reranking
To rerank the retrieved documents for all supported benchmarks, run:
sh run_rerank.sh
To rerank documents for a specific benchmark, run the corresponding command:
python rerank.py --benchmark USMLE_STEP_1 --doc_folder "RETRIEVED_USMLE_STEP_1" --save_folder "RERANKED_USMLE_STEP_1"
python rerank.py --benchmark USMLE_STEP_2 --doc_folder "RETRIEVED_USMLE_STEP_2" --save_folder "RERANKED_USMLE_STEP_2"
python rerank.py --benchmark USMLE_STEP_3 --doc_folder "RETRIEVED_USMLE_STEP_3" --save_folder "RERANKED_USMLE_STEP_3"
python rerank.py --benchmark MedQA --doc_folder "RETRIEVED_MedQA" --save_folder "RERANKED_MedQA"
python rerank.py --benchmark MedExpQA --doc_folder "RETRIEVED_MedExpQA" --save_folder "RERANKED_MedExpQA"
python rerank.py --benchmark PubMedQA --doc_folder "RETRIEVED_PubMedQA" --save_folder "RERANKED_PubMedQA"
Generation
sh run_diagnosis.sh
or
# USMLE STEP 3 Benchmark
python diagnosis.py --benchmark USMLE_STEP_3 --mode "tool_using_open_book" --doc_folder "RERANKED_USMLE_STEP_3" --save_folder "RESULTS_USMLE_STEP_3"
python diagnosis.py --benchmark USMLE_STEP_3 --mode "tool_using_close_book" --doc_folder "RERANKED_USMLE_STEP_3" --save_folder "RESULTS_USMLE_STEP_3"
python diagnosis.py --benchmark USMLE_STEP_3 --mode "direct_prompt" --doc_folder "RERANKED_USMLE_STEP_3" --save_folder "RESULTS_USMLE_STEP_3"
python diagnosis.py --benchmark USMLE_STEP_3 --mode "direct_prompt_with_evidence" --doc_folder "RERANKED_USMLE_STEP_3" --save_folder "RESULTS_USMLE_STEP_3"
python diagnosis.py --benchmark USMLE_STEP_3 --mode "unstructured_prompt_with_evidence" --doc_folder "RERANKED_USMLE_STEP_3" --save_folder "RESULTS_USMLE_STEP_3"
# USMLE STEP 2 Benchmark
python diagnosis.py --benchmark USMLE_STEP_2 --mode "tool_using_open_book" --doc_folder "RERANKED_USMLE_STEP_2" --save_folder "RESULTS_USMLE_STEP_2"
python diagnosis.py --benchmark USMLE_STEP_2 --mode "tool_using_close_book" --doc_folder "RERANKED_USMLE_STEP_2" --save_folder "RESULTS_USMLE_STEP_2"
python diagnosis.py --benchmark USMLE_STEP_2 --mode "direct_prompt" --doc_folder "RERANKED_USMLE_STEP_2" --save_folder "RESULTS_USMLE_STEP_2"
python diagnosis.py --benchmark USMLE_STEP_2 --mode "direct_prompt_with_evidence" --doc_folder "RERANKED_USMLE_STEP_2" --save_folder "RESULTS_USMLE_STEP_2"
python diagnosis.py --benchmark USMLE_STEP_2 --mode "unstructured_prompt_with_evidence" --doc_folder "RERANKED_USMLE_STEP_2" --save_folder "RESULTS_USMLE_STEP_2"
# USMLE STEP 1 Benchmark
python diagnosis.py --benchmark USMLE_STEP_1 --mode "tool_using_open_book" --doc_folder "RERANKED_USMLE_STEP_1" --save_folder "RESULTS_USMLE_STEP_1"
python diagnosis.py --benchmark USMLE_STEP_1 --mode "tool_using_close_book" --doc_folder "RERANKED_USMLE_STEP_1" --save_folder "RESULTS_USMLE_STEP_1"
python diagnosis.py --benchmark USMLE_STEP_1 --mode "direct_prompt" --doc_folder "RERANKED_USMLE_STEP_1" --save_folder "RESULTS_USMLE_STEP_1"
python diagnosis.py --benchmark USMLE_STEP_1 --mode "direct_prompt_with_evidence" --doc_folder "RERANKED_USMLE_STEP_1" --save_folder "RESULTS_USMLE_STEP_1"
python diagnosis.py --benchmark USMLE_STEP_1 --mode "unstructured_prompt_with_evidence" --doc_folder "RERANKED_USMLE_STEP_1" --save_folder "RESULTS_USMLE_STEP_1"
# PubMedQA Benchmark
python diagnosis.py --benchmark PubMedQA --mode "tool_using_open_book" --doc_folder "RERANKED_PubMedQA" --save_folder "RESULTS_PubMedQA"
python diagnosis.py --benchmark PubMedQA --mode "tool_using_close_book" --doc_folder "RERANKED_PubMedQA" --save_folder "RESULTS_PubMedQA"
python diagnosis.py --benchmark PubMedQA --mode "direct_prompt" --doc_folder "RERANKED_PubMedQA" --save_folder "RESULTS_PubMedQA"
python diagnosis.py --benchmark PubMedQA --mode "direct_prompt_with_evidence" --doc_folder "RERANKED_PubMedQA" --save_folder "RESULTS_PubMedQA"
python diagnosis.py --benchmark PubMedQA --mode "unstructured_prompt_with_evidence" --doc_folder "RERANKED_PubMedQA" --save_folder "RESULTS_PubMedQA"
# MedExpQA Benchmark
python diagnosis.py --benchmark MedExpQA --mode "tool_using_open_book" --doc_folder "RERANKED_MedExpQA" --save_folder "RESULTS_MedExpQA"
python diagnosis.py --benchmark MedExpQA --mode "tool_using_close_book" --doc_folder "RERANKED_MedExpQA" --save_folder "RESULTS_MedExpQA"
python diagnosis.py --benchmark MedExpQA --mode "direct_prompt" --doc_folder "RERANKED_MedExpQA" --save_folder "RESULTS_MedExpQA"
python diagnosis.py --benchmark MedExpQA --mode "direct_prompt_with_evidence" --doc_folder "RERANKED_MedExpQA" --save_folder "RESULTS_MedExpQA"
python diagnosis.py --benchmark MedExpQA --mode "unstructured_prompt_with_evidence" --doc_folder "RERANKED_MedExpQA" --save_folder "RESULTS_MedExpQA"
# MedQA Benchmark
python diagnosis.py --benchmark MedQA --mode "tool_using_open_book" --doc_folder "RERANKED_MedQA" --save_folder "RESULTS_MedQA"
python diagnosis.py --benchmark MedQA --mode "tool_using_close_book" --doc_folder "RERANKED_MedQA" --save_folder "RESULTS_MedQA"
python diagnosis.py --benchmark MedQA --mode "direct_prompt" --doc_folder "RERANKED_MedQA" --save_folder "RESULTS_MedQA"
python diagnosis.py --benchmark MedQA --mode "direct_prompt_with_evidence" --doc_folder "RERANKED_MedQA" --save_folder "RESULTS_MedQA"
python diagnosis.py --benchmark MedQA --mode "unstructured_prompt_with_evidence" --doc_folder "RERANKED_MedQA" --save_folder "RESULTS_MedQA"
π Prompt format
System prompt
system_prompt = (
"You are a medical professional specializing in evidence-based medicine (EBM). "
"Your role is to answer questions using a systematic approach, integrating the best available "
"research evidence, clinical expertise, and patient-specific factors."
)
User prompt for multiple-choice QA
tool_evidence_prompt = """Here is the background information and question about the patient:
<background>
{background}
</background>
The available answer options are:
<option>
{option}
</option>
Follow these steps to answer the question:
1. Compare each option with the case details, analyzing key clues in the text to identify the best choice.
2. If the question can be answered through comparison, directly return the best option term with the option capital within <final_result></final_result> tags, placing the explanation outside of the <final_result> tags.
3. If multiple options are plausible or additional evidence is needed for better decision-making, enable search to find credible sources.
4. Analyze the relevance between each document and the patient's presentation, followed by a systematic search to locate relevant evidence applicable to the patientβs case.
5. While we are continuing to provide additional evidence, iterate the previous step to analyze more additional evidence.
6. Once sufficient information is gathered, return the best option term with the option capital within <final_result></final_result> tags, placing the explanation outside of the <final_result> tags."""
User prompt for open-ended QA
tool_evidence_prompt = """Here is the background information and question about the patient:
<background>
{background}
</background>
Follow these steps to answer the question:
1. Compare each option with the case details, analyzing key clues in the text to identify the best choice.
2. If the question can be answered through comparison, directly return the best option term with the option capital within <final_result></final_result> tags, placing the explanation outside of the <final_result> tags.
3. If multiple options are plausible or additional evidence is needed for better decision-making, enable search to find credible sources.
4. Analyze the relevance between each document and the patient's presentation, followed by a systematic search to locate relevant evidence applicable to the patientβs case.
5. While we are continuing to provide additional evidence, iterate the previous step to analyze more additional evidence.
6. Once sufficient information is gathered, return the best option term with the option capital within <final_result></final_result> tags, placing the explanation outside of the <final_result> tags."""
User prompt for cache-and-prune memory bank mechanism
document_revise_template = """Here are the selected relevant documents related to the patient's care:
<document>
{document}
</document>
Review your answer and return the best option term with the option capital within the <final_result></final_result> tags, leave the explanation outside of the <final_result> tags."""
π§° Toolkit description
we designed five specialized tools to serve as the diagnostic aid kit within our AI agent. For question interpretation, the agent uses perform_comparison to handle multiple choice tasks and generate_options for open-ended scenarios, enabling flexible reasoning formats. In particular, generate_options is tailored for scenarios lacking predefined choices, enabling the agent to propose plausible answer candidates from the contextual details of the case. Additionally, the enable_search tool determines whether external evidence is necessary to support a diagnosis. To facilitate evidence retrieval and interpretation, relevance_analysis evaluates the semantic alignment between the patientβs case and retrieved documents, while locate_evidence identifies and grounds specific articles most pertinent to the diagnosis.
π Dataset description
The corpus includes research articles published under Creative Commons licenses from leading biomedical journals indexed in PubMed Central. We also incorporated clinical trial records from ClinicalTrials.gov, filtering for studies that had completed recruitment and were classified as Phase 3 or Phase 4, or that investigated device-based or behavioral interventions. This selection yielded $156,887$ trials as of March 2025. To enhance real-world clinical applicability, we included $1,479$ clinical case reports published by the New England Journal of Medicine (NEJM) between 2016 and March2025. We further adopted pre-indexed corpora of PubMed abstracts and Wikipedia entries from Xiong et al., which have demonstrated strong utility for medical question answering (QA) tasks. Finally, we leveraged $8,226$ open-access medical textbooks from the NLM LitArch Open Access Subset, hosted by the U.S. National Library of Medicine.
π Benchmarks and results
Benchmark datasets
We evaluated our system using five medical question answering benchmarks: the United States medical
licensing examination (USMLE) Steps 1-3, free-form multiple-choice open-domain medical QA (MedQA), and
medical explanation-based QA (MedExpQA) (Table 3). Each benchmark includes clinical case descriptions,
multiple-choice options, and a correct answer.
Multiple-choice QA performance
We manually evaluated the accuracy of all models, including BioMistral (7B), OpenBioLLM (8B and 70B), UltraMedical (8B and 70B), and PodGPT (70B).
Open-ended QA performance
We manually evaluated the performance of all models, including BioMistral (7B), OpenBioLLM (8B and 70B), UltraMedical (8B and 70B), and PodGPT (70B), using three embedding-based metrics: BERTScore F1 computed with deberta-xlarge-mnli, similarity scores from SFR-Embedding-2_R, and similarity scores from gte-Qwen2-7B-instruct models.
We provide evaluation code here.
Tool-usage analysis
We analyzed the agent's tool usage patterns, and provide our code (Figure 2(a)) and code (Figure 2(b)) to generate these figures.
Ablation study
We compared performance with and without tool access to evaluate the impact of incorporating tools into the agentic pipeline.
π₯ Real-world deployment
For real-world deployment, please refer to the vLLM Distributed Inference and Serving and OpenAI Compatible Server. We provide a deployment script here.
At the time, the vLLM version we were using was
0.6.3to serve the Qwen2.5 72B model. Please check this version.
vLLM can be deployed as a server that implements the OpenAI API protocol. This allows vLLM to be used as a drop-in replacement for applications using OpenAI API. By default, it starts the server at http://localhost:8000.
VLLM_RPC_TIMEOUT=100000 vllm serve Qwen/Qwen2.5-72B-Instruct \
--trust-remote-code \
--dtype bfloat16 \
--max-model-len 32768 \
--tensor_parallel_size 4 \
--gpu-memory-utilization 0.95 \
--api-key token-abc123 \
--enable-auto-tool-choice \
--tool-call-parser hermes
Please check here if you wanna change Engine Arguments.
After you download the Qwen model, you need to change the default prompt in the tokenizer_config.json file (this line) by changing the You may call one or more functions to assist with the user query. to You should only call one tool at a time to assist with the user query..
The commands used to serve the open-source scientific and biomedical language models evaluated in this work are provided below:
Model: BioMistral-7B
Link: https://huggingface.co/BioMistral/BioMistral-7B
VLLM_RPC_TIMEOUT=10000 vllm serve BioMistral/BioMistral-7B \
--trust-remote-code \
--dtype bfloat16 \
--max-model-len 2048 \
--distributed-executor-backend mp \
--tensor_parallel_size 1 \
--gpu-memory-utilization 0.95 \
--api-key token-abc123 \
--max-num-seqs 1
Model: aaditya/Llama3-OpenBioLLM-8B
Link: https://huggingface.co/aaditya/Llama3-OpenBioLLM-8B
VLLM_RPC_TIMEOUT=10000 vllm serve aaditya/Llama3-OpenBioLLM-8B \
--trust-remote-code \
--dtype bfloat16 \
--max-model-len 8192 \
--distributed-executor-backend mp \
--tensor_parallel_size 1 \
--gpu-memory-utilization 0.95 \
--api-key token-abc123 \
--tokenizer meta-llama/Meta-Llama-3-8B-Instruct
Model: aaditya/Llama3-OpenBioLLM-70B
Link: https://huggingface.co/aaditya/Llama3-OpenBioLLM-70B
VLLM_RPC_TIMEOUT=10000 vllm serve aaditya/Llama3-OpenBioLLM-70B \
--trust-remote-code \
--dtype bfloat16 \
--max-model-len 8192 \
--distributed-executor-backend mp \
--tensor_parallel_size 4 \
--gpu-memory-utilization 0.95 \
--api-key token-abc123 \
--tokenizer meta-llama/Meta-Llama-3-70B-Instruct
Model: TsinghuaC3I/Llama-3.1-8B-UltraMedical
Link: https://huggingface.co/TsinghuaC3I/Llama-3.1-8B-UltraMedical
VLLM_RPC_TIMEOUT=10000 vllm serve TsinghuaC3I/Llama-3.1-8B-UltraMedical \
--trust-remote-code \
--dtype bfloat16 \
--max-model-len 8192 \
--distributed-executor-backend mp \
--tensor_parallel_size 1 \
--gpu-memory-utilization 0.95 \
--api-key token-abc123 \
--max-num-seqs 1
Model: TsinghuaC3I/Llama-3-70B-UltraMedical
Link: https://huggingface.co/TsinghuaC3I/Llama-3-70B-UltraMedical
VLLM_RPC_TIMEOUT=10000 vllm serve TsinghuaC3I/Llama-3-70B-UltraMedical \
--trust-remote-code \
--dtype bfloat16 \
--max-model-len 8192 \
--distributed-executor-backend mp \
--tensor_parallel_size 4 \
--gpu-memory-utilization 0.95 \
--api-key token-abc123
Model: PodGPT 70B
Link: https://huggingface.co/shuyuej/Llama-3.3-70B-Instruct-2048/tree/main/checkpoint-18640
VLLM_RPC_TIMEOUT=10000 vllm serve meta-llama/Llama-3.3-70B-Instruct \
--trust-remote-code \
--dtype bfloat16 \
--max-model-len 8192 \
--distributed-executor-backend mp \
--tensor_parallel_size 4 \
--gpu-memory-utilization 0.95 \
--api-key token-abc123 \
--enable-lora \
--lora-modules adapter=Llama-3.3-70B-Instruct-2048/checkpoint-18640
π§ Algorithm
Given a patientβs background and clinical question, the AI agent dynamically determines whether external evidence is required and autonomously invokes the appropriate tools.
When evidence retrieval is enabled, the system:
- Retrieves the top-K candidate documents from the medical evidence database.
- Reranks the candidates and selects the top-R most relevant documents.
- Processes the reranked documents incrementally in batches.
- Identifies and grounds relevant evidence from each batch.
- Stores useful evidence in a cache-and-prune memory bank while removing irrelevant information from the active context.
- Continues searching and grounding until sufficient evidence has been collected.
- Generates the final answer using the patient information, reasoning history, and grounded evidence retained in memory.
This iterative design allows the agent to integrate evidence beyond the modelβs effective context-window limit while ensuring that its final response is informed by the most relevant medical information.
πΌοΈ Structure of the code
At the root of the project, you will see:
.
βββ config.yml
βββ config_benchmark.yml
βββ retrieve.py
βββ rerank.py
βββ diagnosis.py
βββ run_retrieve.sh
βββ run_rerank.sh
βββ run_diagnosis.sh
βββ lib
β βββ framework.py
β βββ prompts.py
β βββ tools.py
βββ database
β βββ rag.py
βββ benchmarks
β βββ MedExpQA
β βββ MedQA
β βββ PubMedQA
β βββ USMLE
βββ evaluation-open-ended-QA
β βββ bert_score.py
β βββ GTE-embedding-Model.py
β βββ SFR-embedding-Model.py
βββ results
β βββ Ablation-study
β βββ Multiple-choice-QA
β βββ Open-ended-QA
β βββ Qwen3-models-for-rebuttal
βββ utils
βββ answer_extraction.py
βββ benchmark_utils.py
βββ utils.py
π Citation
If you find our work useful in your research, please consider citing it in your publications. We provide a BibTeX entry below.
@article{Jia2026agenticsystem,
title = {Agentic memory-augmented retrieval and evidence grounding for medical question-answering tasks},
author = {Shuyue Jia and Subhrangshu Bit and Varuna H. Jasodanand and Yi Liu and Vijaya B. Kolachalama},
journal = {International Journal of Medical Informatics},
volume = {212},
pages = {106339},
year = {2026},
issn = {1386-5056},
doi = {https://doi.org/10.1016/j.ijmedinf.2026.106339},
url = {https://www.sciencedirect.com/science/article/pii/S1386505626000791},
}
π§ Contact
Core Contributor and Maintainer:
Other Contributor and Maintainer:
If you have any questions, please drop us an email at brucejia@bu.edu.
π¨ Contributions
We always welcome contributions to help make our Agentic Medical RAG system better. If you would like to contribute, please submit a pull request.
π Acknowledgements
This repository is maintained by members of the Kolachalama Laboratory in Boston, MA.
- Downloads last month
- 32
